Zokinvy extended life by an average of 2.5 years (over the course of 11 years) in young people with progeria or PDPL.
Young people who received Zokinvy had lower blood pressure and lower risk of
The earlier Zokinvy was given, the greater the benefit.
Zokinvy was shown to reduce or delay the effects of many symptoms of progeria and PDPL, including heart and bone problems.
With the chance for a longer life, your family member with progeria or PDPL can do more than they had ever imagined.
Zokinvy has a well-studied safety and tolerability profile in young people 12 months of age and older with progeria or PDPL.
In the clinical studies, young people receiving Zokinvy experienced mild to moderate diarrhea and vomiting, decreased appetite, and nausea.
Gastrointestinal side effects can be successfully managed with supportive care and generally decreased over time.
Side effects occurred most often during the first month of treatment.
Approximately 90 young people with progeria or PDPL participated in clinical studies of Zokinvy; only 4 discontinued due to side effects.
Zokinvy dosage can be adjusted to manage side effects.
IMPORTANT SAFETY INFORMATION
Do not take ZOKINVY if you are taking:
WHAT IS Zokinvy® (lonafarnib)?
ZOKINVY (zoh-KIN-vee) is a prescription medicine used to treat Hutchinson-Gilford Progeria Syndrome and some types of Progeroid Laminopathies known as processing-deficient Progeroid Laminopathies. These illnesses are caused when the body makes harmful proteins called progerin and progerin-like proteins.